Researchers at Kanazawa University in Japan have developed a blood-based gene expression test that detected 90% of early-stage pancreatic cancers in a study published in the journal Cancer Science on July 15, 2026. The test analyzes microRNA signatures in blood samples to identify pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.
Pancreatic cancer has a five-year survival rate of about 10% because it is often diagnosed at advanced stages. Early detection could significantly improve outcomes. In the study, the test achieved 90% sensitivity for stage I and II cancers, with a specificity of 98%.
The researchers used machine learning to analyze microRNA expression patterns from 1,200 participants, including 400 with pancreatic cancer. The test is now being validated in a larger clinical trial involving multiple hospitals in Japan.
If confirmed, this approach could enable routine screening for high-risk individuals, such as those with a family history of pancreatic cancer or certain genetic mutations. The test is not yet approved for clinical use outside of research settings.
